Novartis India: agrochemical spin off will improve numbers
Novartis India is a 50.99% subsidiary of the Novartis Switzerland, the world leader in pharmaceuticals and agrochemicals. The company has 5 brands that contribute almost 45% of its formulation sales
% Pharma Sales (approx)
Otrivin (Nasal decongestation)
Macalvit (calcium Supplement)
The international parent has proposed the separation of its agrochemical arm and its merger with the agrochemical arm of Astra Zeneca to form a new company Syngenta. In India too the same process is underway. This is similar to the move that Wockhardt India has made in India i.e. separating its agrochemical arm and becoming a focused pharma company.
Healthcare (this includes the vision care division and the animal health division) contributes approx. 50% of the Novartis total turnover. The overall operating margins of the company are around 17% and these can be expected to increase to around 22% post the hive off of the agrochemical division. Also, the company would be able to reduce its working capital requirements since the inventory days and debtors days can almost be halved from the present levels of 70 days and 55 days respectively.
for treatment of advanced breast cancer
for management of Alzheimer's disease
for treatment of epilepsy and panic disorders
for treatment of TB
for treatment of TB
Thus the spin off would leave Novartis India with a stable non–seasonal business (since for agro–chemical business, the first half is normally much better than the second half). Besides, the company has launched five new products over the last two years (see table) all of which are out of the purview of the Drug Price Control Order. This can be expected to improve the margins further.
The improvement in profits, the removal of a seasonal business, the introduction of new products coupled with the almost zero debt status of the company should spell good times for the company. The stock quotes at Rs 618 (52 week range: 1436/618) an earning multiple of 26 times its FY99 earnings.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India. Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: firstname.lastname@example.org. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407